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ABSTRACT 17 
Ankyrin repeat (ANK) domains are one of the most abundant motifs in eukaryotic proteins. ANK proteins are rare 18 
amongst viruses with the exception of poxviruses, which presumably acquired them from the host via horizontal gene 19 
transfer. The architecture of poxvirus ANK proteins is however different from their cellular counterparts and this 20 
precludes a direct acquisition event. Here we combine bioinformatics analysis and quantitative proteomics to discover 21 
a new class of viral ANK proteins with a domain organisation that relates to cellular ANK proteins. These non-canonical 22 
viral ANK proteins, termed ANK/BC, interact with host Cullin-2 via a C-terminal BC box resembling that of cellular 23 
Cullin-2 substrate adaptors such as the von Hippel-Lindau protein. Mutagenesis of the BC box-like sequence 24 
abrogates binding to Cullin-2, whereas fusion of this motif to an ANK-only protein confers Cullin-2 association. We 25 
demonstrate that these viral ANK/BC proteins are potent immunomodulatory proteins suppressing the activation of the 26 
pro-inflammatory transcription factors NF-κB and IRF-3 and the production of cytokines and chemokines including 27 
interferon, and that association with Cullin-2 is required for optimal inhibitory activity. ANK/BC proteins exist in several 28 
orthopoxviruses and cluster into 2 closely related orthologue groups in a phylogenetic lineage that is separate from 29 
canonical ANK/F-box proteins. Given the existence of cellular proteins with similar architecture, viral ANK/BC proteins 30 
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may be closely related to the original ANK gene acquired by an ancestral orthopoxvirus. These findings uncover a 31 
novel viral strategy to antagonise innate immunity and shed light on the origin of the poxviral ANK protein family. 32 
 33 
 34 
IMPORTANCE 35 
Viruses encode multiple proteins aimed at modulating cellular homeostasis and antagonising the host anti-viral 36 
response. Most of these genes were originally acquired from the host and subsequently adapted to the virus 37 
advantage. ANK proteins are common in eukaryotes, but unusual amongst viruses with the exception of poxviruses 38 
where they represent one of the largest protein families. We discover here the existence of a new class of viral ANK 39 
proteins, termed ANK/BC, that provide new insights on the origin of poxvirus ANK proteins. ANK/BC proteins target the 40 
host E3 ubiquitin ligase Cullin-2 via a C-terminal BC box domain and are potent suppressors of the production of 41 
inflammatory cytokines including interferon. The existence of cellular ANK proteins with similar architecture suggests 42 
the acquisition of a host ANK/BC gene by an ancestral orthopoxvirus and its subsequent duplication and adaptation to 43 
widen the repertoire of immune evasion strategies.  44 
 45 
 46 
INTRODUCTION 47 
The Ankyrin repeat (ANK) motif is a 33-amino acid sequence that mediates protein-protein interactions (1, 2). ANK 48 
proteins are amongst the most common structural motifs in eukaryotic cells and have a wide range of functions 49 
including cytoskeletal regulation, transcriptional activation or signalling transduction. Well-studied examples of ANK 50 
proteins are the Ankyrin family, which connect integral membrane proteins to the spectrin-actin cytoskeleton (3), or the 51 
regulation of the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) by the inhibitor of kB (IκB)-α, an 52 
ANK protein that binds and retains NF-κB in the cell cytosol in an inactive form (4). Although uncommon in viruses, 53 
ANK proteins are abundant in poxviruses. Between 30 to 50 ANK proteins exist in fowlpox or canarypox viruses, and 54 
up to 15 ANK orthologue groups can be found in cowpox virus (CPXV), most of which are conserved across 55 
poxviruses infecting mammals including variola virus (VARV) (5). A notable exception is molluscum contagiosum virus 56 
(MCV), a poxvirus infecting humans that lacks all ANK proteins (6). The origin of the poxviral ANK proteins is unknown, 57 
but they are believed to have been acquired by one or several horizontal gene transfer events from eukaryotic hosts 58 
and subsequently duplicated (5, 7).  59 
 60 
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Poxviruses are large dsDNA viruses infecting a wide spectrum of species ranging from insects to humans. Poxviruses 61 
infecting vertebrates are grouped into the subfamily Chordopoxvirinae and are currently classified into 10 different 62 
genera. Human pathogens such as VARV, the causative agent of smallpox, and vaccinia virus (VACV), the vaccine 63 
used to eradicate smallpox, belong to the genus Orthopoxvirus (OPV), which also includes animal pathogens with 64 
zoonotic potential such as CPXV and monkeypox virus (MPXV), or with very restricted host range such as ectromelia 65 
virus (ECTV) and camelpox virus (CMLV). Approximately 50 % of the genes identified in all sequenced 66 
chordopoxviruses are conserved and locate in the central region of the linear genome, whereas the remaining 50 % 67 
are genus- or species-specific and encode factors manipulating host responses (8, 9). Many of these modulatory 68 
factors are dedicated to host immune evasion, in particular the suppression of innate immune responses mediated by 69 
interferon (IFN) responsive factors (IRFs) and NF-κB and hence the production of IFN and other pro-inflammatory 70 
mediators that induce the anti-viral state (10). ANK proteins are commonly found on the genome termini and in 71 
agreement with their genomic location, some have been shown to modulate host range and cellular immune signalling. 72 
For instance, VACV protein K1 is necessary for VACV replication in various mammalian cell lines (11-16) and has 73 
been reported to modulate the activation of protein kinase R (17) and (18). More recently, VARV protein G1 and its 74 
orthologues ECTV 002, CPXV 006 and MPXV 003 were shown to interact with the NF-κB precursor p105 and to block 75 
NF-κB activation (19-22).  76 
 77 
A unique feature of some poxviral ANK proteins is their ability to associate with a Cullin-RING ubiquitin E3 ligase (CRL) 78 
containing S-phase associated protein kinase (Skp)-1 and Cullin-1 (also known as SCF1 [Skp-1, Cullin-1, F-box]) (23). 79 
In cells, CRL-1 complexes target cellular proteins for ubiquitylation by the use of F-box-containing proteins (24), which 80 
associate with Skp-1 and Cul-1 via an N-terminal F-box domain and recognise substrates via a second, independent 81 
protein-binding domain (25). Viral ANK proteins contain a C-terminal motif that resembles cellular F-box domains and 82 
mediates interaction with Skp-1 (26). The poxviral F-box (also known as PRANC domain) is thereby proposed to hijack 83 
the cellular CRL-1 complex and redirect its ubiquitin targeting activity towards cellular substrates recognised by the 84 
ANK domain in a manner that is beneficial for the virus. Although the identity of these cellular substrates remains in 85 
most cases elusive, multiple poxviral ANK proteins have been shown to interact with CRL-1 experimentally (19, 22, 23) 86 
or to contain predicted F-box domains (7, 27). As a consequence, viral ANK proteins are structurally divided in ANK/F-87 
box proteins and ANK only proteins.  88 
 89 
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The origin and function of the majority of poxviral ANK proteins remain unknown. Here we combined computational 90 
analysis and unbiased quantitative proteomics to discover a new class of viral ANK proteins termed ANK/BC. ANK/BC 91 
proteins combine ANK domains with a C-terminal BC box to target the host E3 ligase Cullin-2. We demonstrate that 92 
these viral ANK/BC proteins are potent immunomodulatory proteins inhibiting innate immune responses via the 93 
suppression of NF-κB and IRF-3 activation. Viral ANK/BC proteins targeting Cul-2-based CRLs represent a novel viral 94 
strategy to prevent innate immune activation and shed light into the origin of the poxviral ANK protein family.  95 
 96 
RESULTS 97 
ECTV protein 010 is a non-canonical ANK protein that binds Cul-2 98 
To assess the relationships amongst poxviral ANK proteins, we initially retrieved the 181 predicted ANK proteins from 99 
13 species belonging to the OPV genus and established their phylogenetic distribution (Fig. 1A). We identified 15 100 
different orthologue groups as previously proposed (27), but also noticed that groups IV and VI clustered together 101 
separate from the other groups, indicating a closer relationship between these two groups relative to others. Group IV 102 
included ECTV protein 010 and CPXV protein 016 amongst others, whereas group VI included CPXV protein 019. 103 
Previous work from others identified a family of ANK/F-box proteins in ECTV that regulate NF-κB (22, 28, 29). ECTV 104 
010 was, however, not included in that family. To identify potential differences between 010 and the ANK/F-box 105 
proteins, we compared the sequence of all 8 predicted ANK proteins in ECTV. Alignment of the C-terminal tails 106 
extending from the ANK domains of these proteins identified the consensus sequence ϕ-Pro-X2-ϕ-X3-ϕ (where ϕ 107 
represents a hydrophobic amino acid and X represents any amino acid) of the F-box domain in the proteins 002/171, 108 
005, 154 and 165 (Fig. 1B). Proteins 021 and 022 did not have any C-terminal extension since these are ANK-only 109 
proteins. Interestingly, protein 010 did have a C-terminal tail of similar length as those observed in ANK-F-box proteins, 110 
but its sequence did not conform to the consensus F-box. The absence of a functional F-box domain was confirmed by 111 
the inability of 010 to pull-down Cul-1 by co-immunoprecipitation (data not shown).  112 
 113 
To gain insights into the biology of this non-canonical ANK protein, we performed unbiased quantitative proteomics on 114 
010 using stable isotope labelling of amino acids in cell culture (SILAC). Isotope-labelled HEK293T cells were 115 
transfected with FLAG-tagged 010 or the corresponding empty vector (EV) in triplicate and subjected to FLAG 116 
immunoprecipitation 24 h later. Eluates were combined and analysed by mass spectrometry to identify potential 117 
interacting partners of 010. Out of the >500 proteins reliably identified, very few were significantly enriched in the 010 118 
pull-down compared to the EV condition (Data Set S1). Amongst these the E3 ubiquitin ligase Cul-2 showed the 119 
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highest fold increase (Fig. 1C). We did not detect traces of Cul-1 or any other Cul protein in association with 010. To 120 
test whether 010 interacted with Cul-2, we performed FLAG immunoprecipitation upon transfection of FLAG-010 and 121 
myc-Cul-2. Despite the low expression levels observed for 010, anti-myc immunoblotting revealed an interaction 122 
between 010 and Cul-2 that did not occur with other proteins containing the same tags (Fig. 1D). Furthermore, 010 123 
interacted with endogenous levels of Cul-2 as well as other components of Cul-2 complexes such as Elongin B and 124 
Roc1 (Fig. 1E).  125 
 126 
ECTV 010 targets Cullin-2 via a C-terminal BC box 127 
Given the nature of Cul-2 as a ubiquitin ligase, we first addressed whether the 010-Cul-2 interaction would render 010 128 
susceptible for proteasomal degradation. Cells were transfected with 010 or EV and subsequently treated with the 129 
neddylation inhibitor MLN4924, a drug that blocks the action of cullins (30), or vehicle. Treatment with MLN4924 130 
induced accumulation of p27, a known Cullin target, but did not affect the levels of 010 (Fig. 2A). Thus, ratios between 131 
010 and β-actin remained similar in DMSO- and MLN4924-treated cells (Fig. 2B). We then hypothesised that 010 could 132 
act as a Cul-2 adaptor. The best studied cellular adaptor of Cul-2 is the Von Hippel-Lindau (VHL) protein, which 133 
recruits CRL-2 complexes to degrade hypoxia-inducible factors (31). VHL interacts with Cul-2 via a C-terminal domain 134 
known as Elongin BC box followed by a Cul-2 box (32). A detailed analysis of the 010 amino acid sequence identified a 135 
consensus BC box ([T,S,P]-L-X3-[C,S,A]-X3-φ) at the C terminus (positions 727 to 736), the same region that proved 136 
dissimilar to the F-box domain. To determine whether this region contributed to the ability of 010 to bind Cul-2, a 137 
truncation was first generated in which the last 36 amino acids of 010 including the BC box were deleted. This 138 
construct (ΔBC) expressed at similar levels to wild-type 010, but failed to interact with Cul-2 after immunoprecipitation 139 
(Fig. 2C). We then generated a construct in which the critical Leu, Cys and Ile residues of the cryptic BC motif were 140 
mutated (L728A/C723F, named ‘mut2’; and L728A/C723F/I736A, named ‘mut3’). Both alleles expressed to the same 141 
extent as the ΔBC or WT 010 alleles and failed to coprecipitate with Cul-2, indicating that mutagenesis of Leu and Cys 142 
in the BC box is sufficient to abolish interaction with Cul-2 (Fig. 2D). Next we tested whether the presence of the BC 143 
box of 010 could mediate association with Cul-2 in other viral ANK proteins. 010’s BC box-containing tail was fused to 144 
the C terminus of VACV protein K1, an ANK-only protein containing 9 ANK repeats (33). As expected K1 did not 145 
copurify with Cul-2, but the K1.BC chimera did despite the lower expression levels observed for this fusion protein (Fig. 146 
2E). Taken together, these results demonstrated that 010 is a non-canonical ANK protein that binds to Cul-2 147 
complexes using a C-terminal cryptic BC box.  148 
 149 
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ANK/BC proteins are conserved amongst several OPV 150 
Next we established whether targeting host Cul-2 was a strategy unique to ECTV or was shared by other OPV. We 151 
initially performed a bioinformatics search for ANK proteins containing a BC box pattern in the last third of the protein 152 
(C terminus) as discovered in ECTV 010. Several proteins including CPXV 016, CPXV 019, Horsepox virus 013, 153 
Raccoonpox virus 011 and Skunkpox virus 202 were identified (Fig. 3A). Most of these proteins belonged to the ANK 154 
orthologue groups IV and VI (Fig. 1A). We then exploited SILAC proteomics to identify viral Cul-2 interacting proteins 155 
during infection. Full-length Cul-2 and its dominant-negative N-terminal domain (Cul-2.NTD) tagged with a C-terminal 156 
tandem affinity purification (TAP) tag containing FLAG epitopes were transfected into isotopically labelled HEK293T 157 
cells and subsequently infected for a further 16 h with 2 plaque forming units (PFU) per cell of CPXV strain Brighton 158 
Red. Mass spectrometry analysis of the FLAG immunoprecipitates identified a significant enrichment of the viral ANK 159 
proteins CPXV 016 (the homologue of ECTV 010) and CPXV 019 in the Cul-2 and Cul-2.NTD pull-downs compared to 160 
the EV condition (Data Set S2), demonstrating that these proteins interact with Cul-2 during virus infection. No other 161 
viral proteins were significantly enriched. To confirm that these proteins interacted with Cul-2, their codon-optimised 162 
sequences were cloned and over-expressed in HEK293T cells together with myc-Cul-2. Both proteins co-precipitated 163 
with Cul-2 in conditions in which the ANK-only protein K1 did not (Fig. 3B). Taken together these data reveal that 164 
poxviral ANK orthologue groups IV and VI represent a novel class of viral ANK proteins targeting host Cul-2.  165 
 166 
ANK/BC proteins are potent inhibitors of innate immune signalling 167 
We then aimed to ascribe a function to the newly identified ANK/BC proteins. ECTV protein 010 is an uncharacterised 168 
protein conserved across ECTV strains that is located close to the left genome terminus downstream of an early 169 
promoter element (34, 35). These features supported a potential immunomodulatory role for protein 010. To address 170 
this possibility, we first employed reporter gene assays in cells transfected with either 010 or EV (Fig. 4A). Expression 171 
of 010 reduced the activation of an IFN-β-Luc reporter upon infection with Sendai virus (SeV), a strong inducer of IFN-β 172 
production (Fig. 4B), but did not affect the activation of the anti-viral signalling mediated by the Janus kinase/signal 173 
transducers and activators of transcription (JAK/STAT) pathway in response to IFN-β (Fig. 4C). 010 also blocked 174 
activation of the IFN-β reporter triggered by the over-expression of the Toll-Interleukin-1 receptor (TIR) adaptor TRIF 175 
(Fig. 4D), the RNA sensor RIG-I (Fig. 4E) and the cytosolic DNA sensors cGAS and STING (Fig. 4F). We further 176 
mapped the inhibitory action of 010 using luciferase reporters specific for IRF-3, NF-κB or mitogen-activated protein 177 
kinase (MAPK)/activator protein 1 (AP-1), the 3 transcription factors coordinating optimal type I IFN responses. 178 
Expression of 010 blocked IRF-3 signalling downstream of TRIF (Fig. 4G), RIG-I (Fig. 4H) and, to a lesser extent, 179 
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cGAS/STING (Fig. 4I). Likewise, activation of NF-κB by TRIF (Fig. 4J), RIG-I (Fig. 4K) or cGAS/STING (Fig. 4L) was 180 
also significantly reduced by 010. Conversely, no effect was observed on the activation of the MAPK/AP-1 reporter 181 
upon treatment with phorbol 12-myristate 13-acetate (Fig. 4M).  182 
 183 
We also studied the ability of CPXV 016 and 019 in modulating innate immune signalling. Cells were transfected with 184 
IFN-β and NF-κB reporter constructs and RNA sensing, DNA sensing and TLR signalling pathways were stimulated by 185 
over-expression of RIG-I, cGAS/STING and TRIF, respectively, in the presence or absence of CPXV 016 or CPXV 186 
019. CPXV 016 inhibited IFN-β (Fig. 5A) and NF-κB (Fig. 5B) activation downstream of multiple PRR like ECTV 010, 187 
confirming the broad and potent inhibitory role of this viral protein. Conversely, CPXV 019 was able to block TLR 188 
signalling, but failed to affect RNA and DNA sensing pathways (Fig. 5A and 5B).  189 
 190 
ANK/BC proteins suppress the production of CXCL10, CCL5 and IFN 191 
To confirm the immunomodulatory capacity of ANK/BC proteins, quantitative PCR and ELISA were performed. An 192 
inducible cell line expressing FLAG-010 upon addition of doxycycline (Dox) was generated (Fig. 6A). Cells were 193 
treated with Dox for 24 h and subsequently infected with SeV for a further 24 h before the expression levels of the 194 
cytokines IFN-β, CXCL10 and CCL5 were measured by quantitative PCR. SeV infection induced ~30 fold increase in 195 
IFN-β expression and this was reduced to <10 fold by 010 in a statistically significant manner (Fig. 6B). Similarly, 196 
expression levels of cytokines CXCL10 (Fig. 6C) and CCL5 (Fig. 6D) were also reduced in the presence of 010. 197 
Finally, levels of soluble CXCL10 and CCL5 were measured by ELISA. In agreement with mRNA quantitation, 198 
expression of 010 markedly reduced SeV-induced levels of CXCL10 and CCL5 (Fig. 6E and 6F). Collectively, these 199 
results demonstrate that ANK/BC proteins are potent immunomodulators suppressing the production of type I IFN and 200 
innate immune mediators downstream of multiple PRRs.  201 
 202 
Association with Cul-2 correlates with ANK/BC optimal inhibitory activity 203 
Finally, we addressed the impact of the BC box on the ability of 010 to inhibit innate immunity. Mutants of 010 unable 204 
to bind to Cul-2 as well as wild-type 010 were over-expressed and their ability to block intracellular signalling was 205 
assessed. Contrary to wild-type, 010 mutants ΔBC, mut2 and mut3 were significantly impaired in their ability to 206 
suppress NF-κB activation stimulated by the addition of TNFα (Fig. 7A). We then assessed this inhibition at multiple 207 
doses of 010 and their mutants and confirmed that all constructs unable to bind Cul-2 were also unable to suppress 208 
NF-κB activation irrespective of the dose tested (Fig. 7B). A similar trend was observed when assessing IFN-β 209 
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activation. Whilst wild-type 010 significantly inhibited the activation of the IFN-β reporter after TRIF over-expression, 210 
the 010 mutants ΔBC, mut2 and mut3 showed more modest inhibitory capacity (Fig. 7C). Contrary to NF-κB signalling, 211 
all the mutants suppressed IFN-β activation as well as wild-type 010 at higher doses (Fig. 7D), highlighting a possibility 212 
for different mechanisms of inhibition of these signalling pathways. Similar results were obtained when stimulating the 213 
NF-κB reporter with interleukin (IL)-1β and when stimulating the IFN-β reporter with RIG-I over-expression (data not 214 
shown). These data demonstrated that optimal suppression of innate immune signalling by 010 requires the presence 215 
of an intact C-terminal BC box, strongly suggesting that interaction with host Cul-2 is needed for this function. 216 
Collectively these results reveal for the first time the poxviral targeting of Cul-2 via molecular mimicry of a cellular Cul-2 217 
interacting motif to antagonise antiviral signalling and IFN-β production.  218 
 219 
DISCUSSION 220 
The ANK motif is one of the most abundant in nature, particularly in eukaryotes, where it is typically involved in protein-221 
protein interactions. ANK proteins also constitute the largest family of poxvirus proteins where it represents up to 15 % 222 
of the virus proteome (5, 26, 36, 37). Most poxviral ANK proteins contain a conserved C-terminal domain homologous 223 
to the cellular F-box domain that is present in CRL-1 substrate adaptor proteins (23, 26). Cellular F-box proteins use 224 
the F-box sequence to recruit CRL-1 and direct its E3 ubiquitin ligase activity towards proteins recruited via an 225 
independent protein-protein interaction domain (25). Although very few substrates have been identified for poxvirus 226 
ANK/F-box proteins, it is believed that viral ANK/F-box proteins act in a similar manner as their cellular counterparts 227 
rather than targeting and inhibiting CRL-1 generically (37). In addition, poxviruses express ANK-only proteins that do 228 
not contain F-box domains, but it is unclear whether these have evolved from full-length ANK/F-box proteins or were 229 
acquired independently (7, 26). Our results demonstrate that a third class of ANK proteins exist in poxviruses, namely 230 
ANK/BC proteins. These proteins do not interact with cellular CRL-1, but rather with CRL-2 complexes. This interaction 231 
is mediated by a motif in their C terminus that mimics the Elongin BC box present in cellular Cul-2 adaptors such as 232 
protein VHL. Mutagenesis of key residues in this motif abolishes binding to Cul-2, whereas its fusion to an ANK-only 233 
protein is sufficient to mediate interaction. The crystal structure of the VHL:ElonginB/C complex has shown that 234 
residues Leu158 and Cys162 in VHL are critical in mediating binding, whereas the third conserved residue in the BC 235 
motif (Val166) provides further hydrophobic interaction (38). This model seems to apply to viral ANK/BC proteins given 236 
that replacement of Leu and Cys residues was sufficient to abrogate binding. Cellular proteins containing BC boxes 237 
can interact with Cul-2 or Cul-5, and this has been shown to be specified by a second motif located downstream of the 238 
BC box that contains a critical Pro and several hydrophobic residues (32, 39). In the case of viral ANK/BC proteins no 239 
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Pro is found downstream of the BC motif and there are no sequences with homology to Cul-2 or Cul-5 boxes. The 240 
entire domain downstream of the BC motif is shorter than in cellular Cul-2 interacting proteins and there is limited 241 
sequence homology to them. Similar to the viral F box (40), it appears that the viral BC box is truncated and has only 242 
retained the most critical residues allowing Cul-2 interaction. This lack of conservation may have hindered its discovery 243 
and suggests the existence of more BC motifs than previously inventoried.  244 
 245 
Despite its presence in all lineages of Chordopoxviruses the origin of the poxvirus ANK proteins remains unclear. The 246 
absence of a cellular protein combining ANK with an F-box domain precludes a direct acquisition event by an ancestor 247 
virus. However, cellular ANK-containing proteins that interact with CRL machinery via a C-terminal adaptor domain do 248 
exist. Suppressor of cytokine signalling (SOCS) proteins interact with CRL-5 and inhibit the JAK/STAT signalling 249 
pathway (41-43). Also, FEM1 proteins interact with CRL-2 to modulate transcriptional activity (44, 45). The discovery of 250 
viral ANK/BC proteins in poxviruses suggests an evolutionary model in which an ancestral ANK/BC gene was acquired 251 
by an ancestor virus common to all lineages of chordopoxviruses and was subsequently duplicated and adapted to 252 
new hosts and functions such as targeting CRL-1 complexes. This ancient gene may have been lost during the 253 
development of the molluscipoxvirus lineage explaining the absence of ANK proteins in MCV. In addition, viral ANK/BC 254 
proteins correspond to the OPV orthologue groups IV and VI, which cluster separately in phylogenetic analysis and are 255 
unique to CPXV and ECTV. The presence of ANK/BC proteins in CPXV – the OPV with the largest set of ANK proteins 256 
- is in line with studies suggesting that this virus is more closely related to the OPV ancestor (8) and that adaptation to 257 
new hosts involved gene loss from a CPXV-like ancestor (46). Therefore, CPXV ANK/BC genes may represent 258 
remnants of the original ANK/BC gene that were lost in other viral groups through adaptation.  259 
 260 
Poxviruses dedicate a large portion of their coding capacity to antagonise host innate immunity. Their antagonism of 261 
NF-κB signalling is, for instance, remarkable and highlights the importance of this transcription factor in the virus’ 262 
biology (10, 47, 48). NF-κB activation relies on the degradation of the inhibitor of κB (IκB)-α by a CRL-1 complex 263 
containing the E3 ligase β-TrCP (49). β-TrCP is one of the 69 F-box proteins predicted to exist in mammalian cells (24, 264 
50). It binds IκBα through a WD40 domain and recruits the CRL-1 machinery via the F-box domain, presumably in 265 
competition with other cellular F-box proteins (25, 51, 52). It is thus reasonable to envisage that adaptation of the BC 266 
box of an original ANK/BC protein into an F-box could have been evolutionarily favoured. This new ANK/F-box 267 
combination would have allowed the virus to hijack the cellular CRL-1 machinery and, in doing so, compete with β-268 
TrCP and prevent IκBα degradation and NF-κB activation. The critical role of β-TrCP action in poxvirus infection is 269 
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highlighted by the existence of a viral Bcl-2-like protein that specifically blocks its ability to recognise and degrade 270 
substrates (53-55). Similarly, the advantage of hijacking CRL-1 is demonstrated by the conservation of the F-box 271 
domain during the expansion of the ANK/F-box family. This expansion presumably increased the repertoire of cellular 272 
substrates recruited to virally assembled CRL-1 complexes. Interestingly, ANK/BC proteins were also potent 273 
suppressors of IRF-3 responses. Contrary to NF-κB inhibition, this function did not require an intact BC box because 274 
both the ΔBC and the point mutants retained considerable inhibitory activity. Thus, ANK/BC proteins may also contain 275 
domains that may function independently of CRL complex formation, a case that has also been described for some 276 
ANK/F-box proteins (56). It is also formally possible that the BC box mediates a novel, yet unknown function that is 277 
required for NF-κB, but not IRF-3, suppression. Taken together, ANK/F-box and ANK/BC proteins evidence the close 278 
interplay between viruses and the host CRL machinery. In the case of poxviruses, this is further emphasised by the 279 
presence of viral adaptors of CRL-3 (37). It remains unknown whether poxviruses utilise other CRLs, but a recent 280 
report demonstrated that MCV targets CRL-5 to degrade p65 (57). This suggests that non-canonical mechanisms for 281 
CRL manipulation may also exist.  282 
 283 
Our results identify a new class of poxviral ANK proteins and demonstrate their potent antagonism of innate immune 284 
signalling. Optimal antagonism required interaction with Cul-2, presumably because binding and degrading a substrate 285 
via CRL-2 machinery is more effective than simply binding the substrate. Both orthologue groups IV and VI proteins 286 
interacted efficiently with Cul-2, but showed different inhibitory capacity against multiple innate immunity signalling 287 
pathways, implying the existence of a third factor (presumably a substrate) unique to each viral adaptor protein. This 288 
substrate(s) would have likely been missed in our proteomics study due to rapid Cul-2-mediated degradation. Although 289 
the substrates of most poxviral ANK CRL adaptors remain unknown, our data demonstrate that in the case of viral 290 
ANK/BC proteins these must be components of the innate immune signalling cascades leading to or regulating IFN 291 
production. Identification of these components will be the subject of future studies. Taken together, we reveal for the 292 
first time the existence of viral ANK proteins adapted to manipulate CRL-2 and the existence of a novel mechanism 293 
used by poxviruses to antagonise the host innate immune response.  294 
 295 
MATERIAL AND METHODS 296 
Cells, viruses and reagents 297 
HEK293T, BS-C-1 and RK-13 were grown in Dulbecco Modified Eagle medium (DMEM, Life Technologies) 298 
supplemented with 10 % heat-inactivated fetal calf serum (FCS, Seralab), 100 U/mL penicillin and 100 μg/mL 299 
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Streptomycin (Pen/Strep, Life Technologies). HEK293T-REx™ were grown as above with the addition of 10 μg/mL 300 
blasticidin (Life Technologies). ECTV strain Moscow was from Antonio Alcami and was expanded in BS-C-1 cells. 301 
CPXV strain Brighton Red was from Geoffrey L. Smith and was expanded in RK-13 cells. Both viruses were titrated by 302 
conventional plaque assay. SeV was a gift from Steve Goodbourn. IL-1β, TNFα and IFN-β were from Peprotech. PMA 303 
was from Santa Cruz Biotechnology. ML4924 was from Cayman Chemical.  304 
 305 
Expression vectors 306 
Gene sequences for ECTV 010, VACV K1, CPXV 016 and CPXV 019 were optimised for their expression in human 307 
cells and purchased from GeneArt (Life Technologies). Genes were subcloned into a pcDNA4/TO expression vector 308 
(Invitrogen) previously modified to express genes in frame with 3 C-terminal copies of the FLAG epitope in tandem. 309 
ECTV 010.ΔBC was obtained by PCR amplification of the gene fragment encompassing residues 1-726. ECTV 010 310 
mutants L728A/C723F and L728A/C723F/I736A were obtained by site-directed mutagenesis using KOD Hot-start DNA 311 
polymerase (Merck-Millipore). Fusion of the ECTV 010 C-terminal 37 amino acids to VACV K1 was performed by 312 
overlapping PCR and subsequently cloned into pcDNA4/TO-3xFLAG. Myc-tagged human Cul-2 was from Wenyi Wei 313 
(58). Cul-2.TAP and Cul-2.NTD.TAP were generated by PCR amplification of full-length Cul-2 or the region 314 
encompassing amino acids 1-454 respectively. PCR amplicons were subsequently ligated into pcDNA4/TO in frame 315 
with a C-terminal TAP tag containing 2 copies of the strep tag and 1 copy of the FLAG tag as previously described (59, 316 
60). FLAG-tagged RIG-I and TAP-tagged cGAS were generated by PCR amplification using cDNA from THP-1 cells. 317 
FLAG-tagged RIG-I.CARD was from Adolfo Garcia-Sastre. FLAG-tagged STING was from Brian J Ferguson. FLAG-318 
tagged GFP and FLAG-tagged TRIFΔRIP (here referred to as TRIF) were from Felix Randow. All constructs were 319 
verified by sequencing. 320 
 321 
Phylogenetic studies 322 
181 ANK protein sequences from OPV were fetched from the Viral Orthologous Clusters (https://virology.uvic.ca/). 323 
Each protein was assigned to a previously described orthology group (27). An individual MSA was done for every 324 
orthologue group and subsequently MSA were merged with makemergetable from MAFFT. A phylogenetic tree was 325 
obtained with RAxML (raxmlHPC -T 4 -m PROTCATAUTO -p 12367 -x 12367 -#100 -f a) (61) after checking good 326 
quality alignment with Gblocks (62). ANK proteins were predicted with hmmscan (HMMER 3.1b2, http://hmmer.org/) 327 
against PFAM database (63), retaining just those with an e-value <0.01 and i-value <0.01. BC box pattern search (in 328 
prosite format: [TSP]-L-x(3)-[CSA]-x(3)-[AILMFVPG]) was performed for all the proteins with emboss fuzzpro (64). 329 
12 
 
Protein sequences with ANK domains and a BC box in the last third of the protein sequence were selected. Protein 330 
sequence terminations were aligned with MAFFT (65).  331 
 332 
SILAC quantitative proteomics 333 
HEK293T cells were cultured for at least 5 times in Arg/Lys-free MEM supplemented with Pen/Strep, dialised FCS and 334 
either unlabelled or stable isotope-labelled forms of Arg and Lys (DC Biosciences). Cells were transfected with 10 μg of 335 
the indicated plasmids using polyethylenimine (PEI, Polysciences) and lysates were subjected to FLAG 336 
immunoprecipitation as described below after total protein normalisation using bicinchoninic acid protein assay 337 
(Pierce). Denatured eluates were combined on a 1:1 ratio and subjected to in-gel tryptic digestion using a ProGest 338 
automated digestion unit (Digilab UK). The resulting peptides were fractionated using an Ultimate 3000 nanoHPLC 339 
system in line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). All spectra were acquired using 340 
Xcalibur 2.1 software (Thermo Scientific) and operated in data-dependent acquisition mode. FTMS1 spectra were 341 
collected at a resolution of 120 000 over a scan range (m/z) of 350-1550, with an automatic gain control (AGC) target 342 
of 300 000 and a max injection time of 100 ms. Precursors were filtered using an Intensity Range of 1E4 to 1E20 and 343 
according to charge state (to include charge states 2-6) and with monoisotopic precursor selection. Previously 344 
interrogated precursors were excluded using a dynamic window (40 s +/- 10 ppm). The MS2 precursors were isolated 345 
with a quadrupole mass filter set to a width of 1.4 m/z. ITMS2 spectra were collected with an AGC target of 20 000, 346 
max injection time of 40 ms and CID collision energy of 35 %.  347 
 348 
Mass spectrometry data analysis 349 
The raw data files were processed and quantified using Proteome Discoverer software v1.4 (Thermo Scientific) and 350 
searched against the UniProt Human database (downloaded 14/09/17; 140000 entries) plus the ECTV 010 protein or 351 
the entire CPXV proteome sequence using the SEQUEST algorithm. Peptide precursor mass tolerance was set at 10 352 
ppm, and MS/MS tolerance was set at 0.6 Da. Search criteria included carbamidomethylation of cysteine (+57.0214 353 
Da) as a fixed modification and oxidation of methionine (+15.9949 Da) and SILAC labels (+6.02 Da (R) or +10.008 Da 354 
(R) and +4.025 Da (K) or + 8.014 Da (K)) as variable modifications. Searches were performed with full tryptic digestion 355 
and a maximum of 1 missed cleavage was allowed. The reverse database search option was enabled and all peptide 356 
data were filtered to satisfy a 1 % false discovery rate. Contaminants, reverse database hits and hits corresponding to 357 
1 single peptide were removed. Protein ratios were calculated and converted into their log2. Putative interaction 358 
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partners were selected when their ratios were above the cut-off (mean + 1.96 SD) and had been identified in at least 359 
two of the three replicates unless otherwise indicated. 360 
 361 
Immunoprecipitation 362 
HEK293T cells were seeded in 10-cm dishes and transfected with 5 μg of the indicated plasmids using PEI. After 24 h 363 
cells were lysed with phosphate buffered saline (PBS) supplemented with 0.5 % NP-40 and protease and phosphatase 364 
inhibitors (Roche). Cleared lysates were incubated with FLAG M2 resin (Sigma) for 16 h at 4 °C. For the analysis of 365 
Cul-2 endogenous complexes the cells were lysed in 50mM Tris-HCl, pH7.5, 250mM NaCl, 1 % NP-40, 1 mM EDTA, 366 
supplemented with 1 mM DTT. Next day the beads were washed 3 times with lysis buffer prior to incubation at 95 °C 367 
for 5 min in Laemmli loading buffer to elute bound proteins. Cleared lysates and FLAG eluates were analysed by SDS-368 
PAGE and immunoblotting. Data shown are representative of at least 3 independent experiments showing similar 369 
results. 370 
 371 
SDS-PAGE and immunoblotting 372 
Samples were resolved by SDS-PAGE and transferred to nitrocellulose membranes (GE Healthcare) using a Trans-373 
Blot semi-dry transfer unit (Bio-Rad). Membranes were blocked in 0.1% Tween PBS supplemented with 5% skimmed 374 
milk (Sigma) and subjected to immunoblotting with the following primary antibodies at the indicated dilutions: FLAG 375 
(Sigma, 1:20,000); Myc (Merck-Millipore, 1:2,000); Cul-2 (Abcam, 1:1,000); Elongin B (Santa Cruz Biotechnology, 376 
1:200); Roc-1 (Cell Signaling, 1:1,000); p27 (Cell Signaling, 1:1,000); α-Tubulin (Upstate Biotech, 1:10,000); β-Actin 377 
(Sigma, 1:2,000). Primary antibodies were detected using IRDye-conjugated secondary antibodies in an Odyssey 378 
Infrared Imager (LI-COR Biosciences). Images were analysed using Odyssey software and quantitative data was 379 
obtained after integration of at least 3 independent experiments.  380 
 381 
Reporter gene assays 382 
HEK293T cells were seeded in 96-well plates and transfected with the indicated reporters and expression vectors 383 
using PEI as described in the figure legends. The reporter plasmids have been described previously (54). After 24 h 384 
the cells were stimulated by infection with SeV for a further 24 h; or by addition of 50 ng/mL of TNFα for 6 h, or 50 385 
ng/mL of IFNβ for 8 h, or 10 ng/mL of PMA for 16 h; or by co-transfection of 30 ng/well of TRIF, 20 ng/well of cGAS 386 
and STING, 5 ng/well of RIG-I.CARD or 50 ng/well of RIG-I unless otherwise indicated. After stimulation cells were 387 
washed with ice-cold PBS and lysed with Passive Lysis Buffer (Promega). Luciferase activity was measured in a 388 
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Clariostar plate reader (BMG Biotech) and firefly and renilla ratios were calculated for each condition. Data were 389 
normalised to mock-infected samples or samples transfected with an empty vector and presented as a fold increase. In 390 
all cases data shown are representative of at least 3 independent experiments showing similar results, each performed 391 
in triplicate and plotted as mean ± SD. 392 
 393 
ECTV 010 Inducible cell line 394 
HEK293T-REx™ were transfected with 010.FLAG using PEI and subjected to end-point limiting dilution in medium 395 
containing 10 μg/mL of zeocin (Life Technologies). After approximately 10 days individual clones were selected and 396 
expanded. 010 expression was tested by immunoblotting upon addition of 2 μg/mL of doxycycline (Dox, Sigma). 397 
Clones showing the highest Dox-dependent expression levels were further selected.  398 
 399 
Quantitative PCR 400 
RNA was purified using the Total RNA Purification Kit (Norgen Biotech). One ug of RNA was transformed into cDNA 401 
using Superscript III reverse transcriptase (Invitrogen). cDNA was diluted 1:5 in water and used as a template for real-402 
time PCR using SYBR® Green PCR master mix (Applied Biosystems) in a LightCycler® 96 (Roche). Expression of 403 
each gene was normalized to an internal control (18S) and these values were then normalized to the non-stimulated 404 
mock-infected control cells to yield a fold induction. Primers used for the detection of CXCL10 (66), CCL5 (54), hIFNβ 405 
(67) and 18S (67) have been described previously. Data shown are representative of at least 3 independent 406 
experiments showing similar results, each performed in triplicate and plotted as mean ± SD. 407 
 408 
ELISA 409 
Cell culture supernatants from virus-infected HEK293T cells grown in 6-well plates were assayed for CXCL10 and 410 
CCL5 using Duoset ELISA reagents (R&D Biosystems) according to the manufacturer’s instructions. Data shown are 411 
representative of at least 2 independent experiments showing similar results, each performed in triplicate and plotted 412 
as mean ± SD. 413 
 414 
Statistical analysis 415 
Statistical significance was determined using a Student’s t-test comparing pairwise each experimental condition to the 416 
control condition, with Welch’s correction where appropriate. 417 
 418 
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 599 
Figure Legends 600 
FIG 1 ECTV protein 010 is a non-canonical ANK protein that binds Cul-2. (A) Phylogenetic tree of OPV ANK proteins. 601 
Orthologue groups are named in roman numerals and highlighted in several colours. Proteins without background 602 
colour could not be assigned to an orthologue group unambiguously. Branch length indicates relationship. (B) 603 
Alignment of the C-terminal terminations of ECTV ANK proteins in comparison to the consensus poxviral F-box 604 
sequence (above). Identical residues are highlighted in black. Similar residues are highlighted in grey. (C) SILAC 605 
proteomics analysis of FLAG immunoprecipitated proteins from cells expressing FLAG-tagged 010 or the 606 
corresponding empty vector (EV). The mean log2 fold increase (010/EV) of each identified protein in three biological 607 
replicates is presented against the mean intensity of those proteins. The data point corresponding to Cul-2 is 608 
highlighted in red. (D) HEK293T cells were co-transfected with FLAG-tagged 010 or RIG-I together with myc-tagged 609 
Cul-2 or TAK-1. After 24 h the cells were lysed and subjected to FLAG immunoprecipitation (IP). Cell lysates (2 %) and 610 
IP samples were analysed by immunoblotting against the indicated proteins. (E) HEK293T cells were transfected with 611 
FLAG-tagged 010 or GFP. After 24 h the cells were lysed and subjected to FLAG IP. Cell lysates (1.25 %) and IP 612 
samples were analysed by immunoblotting against the indicated proteins. 613 
 614 
FIG 2 ECTV 010 targets Cullin-2 via a C-terminal BC box. (A) HEK293T cells were transfected with FLAG-tagged 010 615 
or EV. After 24 h the cells were treated with 1 μM of MLN4924 or vehicle (DMSO) for a further 16 h. Cell lysates were 616 
subjected to immunoblotting against the indicated proteins. (B) Normalised intensity for 010 protein bands after DMSO 617 
or MLN4924 treatment from 3 independent experiments obtained via LI-COR. (C) HEK293T cells were co-transfected 618 
with FLAG-tagged full-length 010 (WT), 010 lacking the last 37 C-terminal amino acids (ΔBC) or RIG-I together with 619 
myc-tagged Cul-2. After 24 h the cells were lysed and subjected to FLAG immunoprecipitation (IP). Cell lysates (2 %) 620 
and IP samples were analysed by immunoblotting against the indicated proteins. (D) HEK293T cells were transfected 621 
with FLAG-tagged full-length 010 (WT), 010.L728A/C723F (mut2), 010.L728A/C723F/I736A (mut 3) or the ANK-only 622 
protein K1 together with myc-tagged Cul-2. After 24 h the cells were lysed and subjected to FLAG IP and 623 
immunoblotting as above. (E) HEK293T cells were transfected with FLAG-tagged 010, GFP, K1 or K1 fused to the last 624 
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37 C-terminal amino acids of 010, together with myc-tagged Cul-2. After 24 h the cells were lysed and subjected to 625 
FLAG IP and immunoblotting as above. Data are representative of at least 3 biological experiments.  626 
 627 
FIG 3 ANK/BC proteins are conserved amongst several OPV. (A) Conservation of the BC box sequence in the 628 
indicated ANK proteins. (B) HEK293T cells were co-transfected with FLAG-tagged 016, 019 or K1 together with myc-629 
tagged Cul-2. After 24 h the cells were lysed and subjected to FLAG immunoprecipitation (IP). Cell lysates (2 %) and 630 
IP samples were analysed by immunoblotting against the indicated proteins. 631 
 632 
FIG 4 ECTV 010 inhibits NF-kB and IRF-3 activation downstream of multiple PRR. (A) Immunoblot from a 633 
representative reporter assay in HEK293T cells transfected with 25 ng/well of 010 or the corresponding empty vector 634 
(EV). Lysates were cleared by centrifugation and subjected to immunoblotting against the indicated proteins. (B) Cells 635 
were transfected with 010 or EV together with 10 ng/well of pTK-Renilla and 70 ng/well of pIFN-β-Luc. After 24 h the 636 
cells were stimulated with Sendai virus (SeV) for a further 24 h and luciferase activity was measured. FLuc/Renilla Luc 637 
ratios were normalised to the non-stimulated (n.s.) control and presented as a fold increase. (C) Cells were transfected 638 
as in (B) but with 70 ng/well of pISRE-Luc and including C6 as a positive control. The cells were stimulated 24 h after 639 
with 50 ng/mL of IFN-β for a further 8 h. (D-F) Cells were transfected as in (B) together with (D) 30 ng/well of TRIF, (E) 640 
5 ng/well of RIG-I-CARD, or (F) 20 ng/well of cGAS and STING each. (G-I) Cells were transfected (D-F) but with 70 641 
ng/well of pISG56.1-Luc. (J-L) Cells were transfected as in (D-F) but with pNF-κB-Luc. (M) Cells were transfected as in 642 
(B) but with 250 ng/well of pAP-1-Luc. In all assays data are presented as mean ± SD and show one representative 643 
experiment of at least three, each performed in triplicate. *p<0.05, **p<0.01 or ***p<0.001, unpaired Student’s t-test. 644 
(G).  645 
 646 
FIG 5 CPXV 016 and 019 inhibit NF-kB and IRF-3 activation. (A-B) HEK293T cells were transfected with 25 ng/well of 647 
010 (black bars), 016 (red bars), 019 (black bars) or the corresponding empty vector (EV, white bars) together with 10 648 
ng/well of pTK-Renilla and 70 ng/well of (A) pIFNβ-Luc or (B) pNF-κB-Luc, as well as 50 ng/well of RIG-I, 20 ng/well of 649 
cGAS and STING each, or 10 ng/well of TRIF. After 16 h the cells were harvested and luciferase activity was 650 
measured. FLuc/Renilla Luc ratios were normalised to the non-stimulated EV control and presented as a fold increase. 651 
In all assays data are presented as mean ± SD and show one representative experiment of at least three, each 652 
performed in triplicate. n.s. non-significant, *p<0.05, **p<0.01 or ***p<0.001, unpaired Student’s t-test. 653 
 654 
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FIG 6 ANK/BC proteins suppress the production of CXCL10, CCL5 and IFN. (A) HEK293T-REx™ cells were induced 655 
with 2 μg/mL of doxycycline (Dox) for 16 h and subjected to immunoblotting against the indicated proteins. (B-D) The 656 
cells were induced with Dox as in (A) and subsequently stimulated with SeV for a further 24 h. RNA expression levels 657 
for (B) IFN-β, (C) CXCL10 and (D) CCL5 were measured by qPCR. Data were normalised to 18S expression levels 658 
and a fold increase over non-stimulated conditions. (E-F) The cells were treated as in (B) and the resulting cell culture 659 
media was subjected to ELISA to detect soluble levels of (E) CXCL10 and (F) CCL5. In all assays data are presented 660 
as mean ± SD and show one representative experiment of at least three, each performed in triplicate. **p<0.01 or 661 
***p<0.001, unpaired Student’s t-test.  662 
 663 
FIG 7 Association with Cul-2 is required for ANK/BC optimal inhibitory activity. (A) HEK293T cells were transfected with 664 
5 ng/well of 010, 010dBC, 010.L728A/C723F (mut2), 010.L728A/C723F/I736A (mut 3) or the corresponding empty 665 
vector (EV) together with 10 ng/well of pTK-Renilla and 70 ng/well of pNF-κB-Luc. After 24 h the cells were stimulated 666 
with TNFα for a further 6 h. FLuc/Renilla Luc ratios were normalised to the non-stimulated (n.s.) EV control and 667 
presented as a fold increase. (B) NF-κB activation was assessed as above but in the presence of increasing doses of 668 
each 010 construct. Luciferase ratios were plotted as a percentage relative to the extent of NF-κB activation observed 669 
in EV-transfected cells stimulated with TNFα. (C) Cells were transfected as in (A) but together with 20 ng/well of TRIF. 670 
After 16 h the cells were harvested and luciferase activity was measured. FLuc/Renilla Luc ratios were normalised to 671 
the non-stimulated (n.s.) EV control and presented as a fold increase. (D) IFNβ activation was assessed as above but 672 
in the presence of increasing doses of each 010 construct. Luciferase ratios were plotted as a percentage relative to 673 
the extent of IFNβ activation observed in EV-transfected cells stimulated with TRIF. In all assays data are presented as 674 
mean ± SD and show one representative experiment of at least three, each performed in triplicate. *p<0.05, **p<0.01 675 
or ***p<0.001, unpaired Student’s t-test.  676 
 677 
Supplemental Material 678 
Data Set S1. SILAC proteomics data for ECTV 010. 679 
 680 
Data set S2. SILAC proteomics data for Cul-2 upon CPXV infection. 681 
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